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Urocortins (Ucns) are members of the corticotropin-releasing factor (CRF) family of peptides. Ucns would have potent eﬀects on
the cardiovascular system via the CRF receptor type 2 (CRF2 receptor). Regulation and roles of each Ucn have been determined
in the vascular system. Ucns have more potent vasodilatory eﬀects than CRF. Human umbilical vein endothelial cells (HUVECs)
express Ucns1-3 mRNAs, and the receptor, CRF2a receptor mRNA. Ucns1-3 mRNA levels are diﬀerentially regulated in HUVECs.
DiﬀerentialregulationofUcnsmaysuggestdiﬀerentialrolesofthoseinHUVECs.Ucn1andUcn2havestrongeﬀectsoninterleukin
(IL)-6 gene expression and secretion in rat aortic smooth muscle A7r5 cells. The increase that we observed in IL-6 levels following
Ucn treatment of A7r5 cells suggests that smooth muscle cells may be a source of IL-6 secretion under physiological stress
conditions. Ucns are important and unique modulators of vascular smooth muscle cells and act directly or indirectly as autocrine
and paracrine factors in the vascular system.
1.Introduction
Corticotropin-releasing factor (CRF) plays a central role in
controlling the hypothalamic-pituitary-adrenal (HPA) axis
during stress [1]. Urocortins (Ucns) are also members of
the CRF family of peptides. Three Ucns have been found
in mammals. Ucn1 is a 40-amino-acid peptide cloned from
the Edinger-Westphal nucleus [2], and Ucn2 and Ucn3 are
identiﬁed in the human genome data base and in mouse
g e n o m i cD N A ,r e s p e c t i v e l y[ 3–5]. Ucn1 and/or Ucn2 is
expressed in the heart, vascular, and peripheral blood cells
[3–8], while the expression of Ucn3 also has been reported
in the human cardiovascular system [9]. The Ucns have been
demonstrated to play important modulatory roles in various
tissues including the brain, immune system, cardiovascular
system and gastrointestinal system, and may be important in
the various stages of atherosclerosis development [10].
The actions of the CRF family peptides are mediated by
at least two distinct G protein-coupled receptors, namely, the
CRF receptor type 1 (CRF1 receptor) [11–13] and CRF re-
ceptor type 2 (CRF2 receptor) [14–16]. These two recep-
tors share 69% amino acid homology [17], but have differ-
ent tissue distributions and pharmacological properties with
respect to ligands [10]. CRF1 receptor is the major subtype
responsible for regulating synthesis and secretion of adre-
nocorticotropic hormone (ACTH) in the pituitary corti-
cotrophs [18], whereas CRF2 receptor with splice variants
is found in the brain and in peripheral sites including the
cardiac myocytes and vascular smooth muscles [19, 20].
CRF has higher aﬃnity for the CRF1 receptor than for the
CRF2 receptor (Figure 1). Ucn1 binds to both the CRF1 and
CRF2 receptors, while Ucn2 and Ucn3 are highly selective for
the CRF2 receptor, with little aﬃnity for the CRF1 receptor
(Figure 1)[ 2, 4, 5].
CRF2b receptor is a member of the Class B heptahelical
G protein-coupled receptors. This receptor is positively cou-
pled to adenylate cyclase and is bound preferentially by the
CRF-related peptides, Ucns. In the rodent, CRF2b receptor
messenger RNA (mRNA) is expressed in the cardiovascular
system, where its levels can be modulated by Ucns [24].
Ribonuclease protection assays show that A7r5 cells express
the CRF2b receptor subtype, which have two isoforms
diﬀering in one codon at the junction of exons 3 and 4 [25].
Ucn induces accumulation of intracellular cAMP via CRF2b
receptor. Ucn induces intracellular cAMP to downregulate
CRF2b receptor mRNA expression in A7r5 cells [25]. CRF22 International Journal of Endocrinology
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Figure 1: Proposed signaling mechanisms of Ucns and CRF recep-
tors in the vascular system. CRF-BP, CRF-binding protein.
ligands or dexamethasone reduces CRF2b receptor mRNA
levels [24]. In addition, a variety of cytokines also reduce
CRF2 mRNA expression [24]. The multifactorial regulation
of CRF2 mRNA expression in the cardiovascular system may
serve to limit the inotropic and chronotropic eﬀects of Ucns
during prolonged physical or immune challenge.
2. ExpressionandRegulation of Ucns in
theVascularSystem
Human umbilical vein endothelial cells (HUVECs) express
Ucns 1–3 mRNAs, and the receptor, CRF2a receptor mRNA,
suggesting an endogenous role of each Ucn via the CRF2a
receptor in HUVECs (Figure 2)[ 21].E n d og e n o u sU cni nt h e
system might act in an autocrine or paracrine manner [26].
Endothelial Ucn1, upregulated by inﬂammatory cytokines
and pitavastatin, suppresses reactive oxygen species produc-
tion in endothelial cells [7]. The data suggest that endothelial
Ucn1 has potent antioxidative properties [7]. Lipopolysac-
charide(LPS)decreasesUcn1mRNAlevels,whileitincreases
Ucn2 and Ucn3 mRNA levels in HUVECs [21]. LPS would
regulate Ucns gene expression levels directly through Toll-
like receptors. After immune stimulation, tumor necrosis
factor (TNF)-α, interleukin (IL)-1, and IL-6, are elevated
in the systemic circulation. These cytokines also increase
the activity of the HPA axis, resulting in the release of
additional ACTH and corticosterone [27, 28]. Among them,
IL-1β is a pleiotropic cytokine with a variety of biological
activities. IL-1β decreases Ucn1 and Ucn2 mRNA levels,
while it increases Ucn3 mRNA levels in HUVECs [21]. These
dataare consistent withchangesin mRNA levels ofUcn1and
Ucn3followingLPS.Therefore,IL-1andLPSmaycontribute
cooperatively to regulate the levels of Ucn1 and Ucn3 mRNA
in the vascular cells.
Forskolin stimulates adenylate cyclase and then intra-
cellular cAMP in HUVECs. Norepinephrine, prostacyclin,
and adiponectin may be candidates for natural ligands to
activate cAMP pathway in HUVECs [29–31]. These peptides
or hormones can regulate Ucns via the cAMP production
in HUVECs, although this association remains speculate.
Ucns also regulate own or other Ucns in an autocrine or
paracrine manner via the cAMP pathway. In fact, forskolin
increases Ucn1 mRNA levels, while it decreases Ucn2 and
Ucn3 mRNA levels in HUVECs. In both the mouse and
human Ucn promoters, there is a consensus cAMP response
element (CRE) site, which has been shown to mediate
the regulation of Ucn expression by cAMP [32]. The CRE
binding protein via the protein kinase A (PKA) pathway may
be involved in this pathway. Ucn2 and Ucn3 mRNA levels are
decreased presumably due to increase in mRNA degradation
or decrease in the mRNA synthesis. Diﬀerential regulation
of Ucns1-3 mRNA may suggest diﬀerential roles of those in
HUVECs.
3. Roles and Action of Urocortins in
theVascularSystem
Recent studies have shown the potent eﬀects of Ucns on the
cardiovascular system. Taken together with the expression of
Ucnsandthereceptor,endogenousUcnshaveaphysiological
roleinthecardiovascularsystem.VasodilatoryeﬀectsofUcns
have been demonstrated in rat tail and basilar arteries [33,
34]. Ucn1 produces vasodilation via the adenylate cyclase
and PKA pathway [34]. Furthermore, Ucn1 and Ucn2 have
more potent vasodilatory and cardiac inotropic eﬀects than
CRF, with a greater potential to increase coronary blood
ﬂow and reduce overall blood pressure [34, 35]. In our pre-
vious study, Ucns1-3 were more potent vasodilators than
CRF in a rat thoracic aorta model (Figure 3)[ 22]. Ucns con-
tribute to vasodilation via p38 mitogen-activated protein
(MAP) kinase and PKA pathways (Figure 1). In vascular
smooth muscle cells, stimulation of CRF2 receptors results
in increased cAMP accumulation via activation of adenylate
cyclase [25]. It is at least possible that increased cAMP levels
contribute to vasorelaxant responses, although the role of
cGMP remains unclear. Ucns exert their vasorelaxant eﬀects
via G α s-cAMP-PKA signaling, leading to downregulation
of the phospholipase Cβ-inositol 1, 4, 5-triphosphatase-
Ca2+ signaling pathway (Figure 1)[ 36]. The Ucns-induced
endothelium-dependent relaxation of rat coronary arteries
would be also attributable to endothelial nitric oxide (NO)
(Figure 1). Ucn2 induces NO production through cAMP-
dependentandCa2+-relatedphosphorylationofextracellular
signal-related kinases (ERKs), Akt, and p38 pathways in
aortic endothelial cells (Figure 1)[ 37]. In addition, we
reported a ﬁrst case of multiple endocrine neoplasia type
II without hypertension, accompanied by thyroid medullary
carcinoma and pheochromocytomas expressing CRF, Ucn1,
and Ucn3 [38]. This case highlights that CRF and Ucn1
secreted from the adrenal pheochromocytomas and thyroid
tumor might induce vasodilation.
Ucn2signiﬁcantlyreducesbloodpressureinhypertensive
rats without aﬀecting heart rate [39]. Long-term Ucn2 treat-
ment in hypertensive rats induces sustained blood pressure
reduction and diminishes the development of hypertension-
induced left ventricular hypertrophy and the deterioration
of left ventricular contractile function [39]. CRF2 receptor
expression levels are preserved, despite chronic stimulation
by Ucn2. Ucn also may play a role in vascular remodelingInternational Journal of Endocrinology 3
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Figure 2: Expression of Ucns and CRF receptors mRNA in HUVECs. A representative image of RT-PCR for Ucns and CRF receptors mRNA
in HUVECs. Reproduction from [21] with permission of the publisher. Copyright 2009, Elsevier.
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Figure 3: Eﬀects of CRF and Ucns on vasodilation. Rat aortae were
incubatedwithmediumalone(control)orwithmediumcontaining
1μM of CRF, Ucn1, Ucn2, or Ucn3 (n = 5). Statistical analyses
wereperformedusingtwo-wayANOVA,followedbyScheﬀe’sFpost
hoc test. Reproduction from [22] with permission of the publisher.
Copyright 2003, Lippincott Wiliams & Wilkins.
[40]. Long-term Ucn treatment not only has hypotensive
eﬀects but also may inhibit development of vascular remod-
eling in mesenteric arteries in spontaneously hypertensive
rats [40]. Together, CRF2 receptor stimulation by Ucn2
may represent a novel approach to the treatment of arterial
hypertension.
Endothelial Ucn1 has potent antioxidative properties.
Treatment with pitavastatin (2mg/day) for 4 weeks increases
the serum Ucn1 level from 11.0 ± 6.5t o1 6 .4 ± 7.3ng/mL
in healthy subjects [7]. Thus, endothelial Ucn1 may protect
cardiomyocytesininﬂammatorylesions.Theselectiveblock-
ade of CRF receptors expressed in human aortic endothelial
cells also indicates that CRF1 receptor signaling mainly
exerts anti-inﬂammatory actions [41]. The beneﬁcial action
of pitavastatin may be, in part, exerted via CRF1 receptor
(Figure 1).
Ucn1 and Ucn2 have strong eﬀects on IL-6 gene expres-
sion and secretion in rat aortic smooth muscle A7r5 cells
[23]. Cyclooxygenase-2 (COX-2) pathway is involved down-
stream in regulation of Ucn-increased IL-6 gene expression
and IL-6 secretion (Figure 4)[ 23]. The increase that we
observed in IL-6 levels following Ucn treatment of A7r5 cells
suggests that smooth muscle cells may be a source of IL-6
secretion under physiological stress conditions. Increased IL-
6 protein levels would be expected to modify both humoral
and cellular immunity [42]. In addition, IL-6 is able to
stimulate ACTH and glucocorticoids secretion [43]. This
combination of actions implies that increased IL-6 levels
may have direct and indirect eﬀects on the immune and
other stress modulations. We have demonstrated previously
thatUcndirectlydownregulatesCRF2b receptormRNAlevels4 International Journal of Endocrinology
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Figure 4: Eﬀects of cyclooxygenase inhibitors on Ucn1- or Ucn2-
induced IL-6 output in A7r5 aortic smooth muscle cells. Cells
were treated in triplicate, with the mean of three independent
experiments (an average in triplicate was considered n = 1; three
experiments n = 3) shown in ﬁgures. Statistical analyses were
performed using one-way ANOVA, followed by Scheﬀe’s F post hoc
test. Cells were preincubated with medium containing indometh-
acin (INDO), NS-398 (NS), or vehicle for 30min then incubated
for 48h with medium containing 100nM Ucn1, Ucn2, or vehicle.
∗P<0.0005 (compared with only Ucn1). #P<0.0005 (compared
with only Ucn2). Reproduction from [23] with permission of the
publisher. Copyright 2006, The Endocrine Society.
[24]. Because cytokines such as IL-1 and IL-6 both decrease
CRF2b receptor mRNA expression [24, 44], it is possible that
Ucn and IL-6 contribute cooperatively to regulate the levels
of CRF2b receptor mRNA in vascular cells. IL-6 may act as an
autocrine and paracrine factor in the vessel wall.
Ucns have been suggested to have roles in regulation of
blood pressure and in the pathophysiology of cardiovascular
disease.Richards’sgroupreportsthatplasmaUcn1innormal
c ontr olsubjectsat7.2±2.9pMissigniﬁcantlylowerthanlev-
els recorded in the non-heart-failure symptomatic patients
(11.1 ± 3.2pM) [45]. Elevated plasma Ucn1 in human
heart failure reﬂects a beneﬁcial compensatory response to
this condition. Serum Ucn2 levels are elevated in mild-
to-moderate systolic dysfunction (12.8 ± 3.6 versus 10.4 ±
3.9pg/mL, resp.) [46] .T h es t u d i e sb yR a d e m a k e re ta l .
suggest that Ucn2 or Ucn3 may have therapeutic potential
in patients with heart failure [47, 48]. Adjunct Ucn2 therapy
with diuretics in heart failure is beneﬁcial, because Ucn2
administration induces sustained improvements in hemo-
dynamics and renal function, in association with inhibition
of multiple vasoconstrictor/volume-retaining systems [49].
These ﬁndings support the therapeutic potential for Ucn2
in heart failure [50]. Ucn3 induces potent inhibition of
sympathetic traﬃc directed toward the heart [51].
Ucn1 is a cardioprotective peptide and is also involved in
cardiac hypertrophy. Ucn1-induced cardiomyocytes hyper-
trophy is associated with regulation of GSK-3β, a pivotal
kinase involved in cardiac hypertrophy, in a phosphatidyl-
inositol-3-kinase- (PI3K-) dependent manner [52]. The
expression of endogenous cardiac Ucns is increased by in
vitro ischemia-reperfusion damage, and the addiction of
e x o g e n o u sU c n si sa s s o c i a t e dw i t hr e d u c t i o no fm y o c a r d i a l
cell death during ischemia-reperfusion damage [53]. There-
fore, Ucns have a signiﬁcant protection against myocardial
ischaemia/reperfusion injury [54, 55].
4. Conclusion
HUVECs express Ucn1, Ucn2, and Ucn3 mRNAs and CRF2a
receptor mRNA. Diﬀerential regulation and roles of Ucns1-3
mRNA are suggested in HUVECs. Ucn1 and 2 stimulate IL-6
gene transcription and secretion via CRF2 receptor activity
in A7r5 aortic smooth muscle cells. Ucns are important and
unique modulators of vascular smooth muscle cells and act
directlyorindirectlyasautocrineandparacrinefactorsinthe
vascular system.
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